Detalles de la búsqueda
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37163621
2.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37172204
3.
Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Ann Hematol
; 103(6): 2013-2020, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38421404
4.
Multistep pathogenesis of chronic myelomonocytic leukemia in patients.
Eur J Haematol
; 109(1): 50-57, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35299281
5.
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
Eur J Haematol
; 107(2): 265-274, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33998054
6.
Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
Int J Mol Sci
; 21(17)2020 Aug 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32842710
7.
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
Int J Mol Sci
; 21(8)2020 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32344757
8.
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance.
Genes Chromosomes Cancer
; 57(11): 547-556, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30248204
9.
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.
Haematologica
; 100(2): 205-13, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25344522
10.
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Ann Hematol
; 93(3): 459-62, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24441915
11.
Proposed score for survival of patients with myelodysplastic syndromes.
Eur J Clin Invest
; 43(11): 1120-8, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24102333
12.
BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial.
EClinicalMedicine
; 66: 102318, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38024477
13.
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
Wien Klin Wochenschr
; 132(3-4): 97-109, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31414181
14.
Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype.
Cancers (Basel)
; 12(7)2020 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32674283
15.
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.
Ann Hematol
; 88(7): 607-11, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19148644
16.
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Cancer Med
; 8(4): 1401-1405, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30888118
17.
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research.
Wien Klin Wochenschr
; 131(17-18): 410-418, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31321531
18.
Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications.
Leuk Lymphoma
; 48(10): 1900-9, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17917959
19.
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Lancet Haematol
; 4(10): e475-e486, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28916311
20.
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Lancet Haematol
; 3(7): e317-29, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27374465